Overview

Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:
0

Participant gender:
All

Summary

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Low doses of interferon alfa may be as effective as high doses. PURPOSE: Randomized phase III trial to compare the effectiveness of low-dose or high-dose interferon alfa in treating patients who have newly diagnosed chronic myelogenous leukemia.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Medical Research Council

Treatments:

Cytarabine
Hydroxyurea
Interferon-alpha
Interferons

Criteria

DISEASE CHARACTERISTICS: Chronic myelogenous leukemia in chronic phase Molecular evidence
of BCR/ABL rearrangement OR Presence of Philadelphia chromosome Eligibility for allogeneic
bone marrow transplantation does not exclude

PATIENT CHARACTERISTICS: Age: Adult Performance status: WHO 0-2 Hematopoietic: Not
specified Hepatic: Bilirubin less than twice normal No severe hepatic problem Renal:
Creatinine less than twice normal No severe renal problem Cardiovascular: No severe
cardiovascular problem Other: No contraindication to interferon therapy No history of
severe depression No pregnant women Effective contraception required of fertile women

PRIOR CONCURRENT THERAPY: No prior therapy Prior therapeutic or back-up leukapheresis
allowed Hydroxyurea may be started up to 4 weeks prior to entry